Clinical Education

For every clinician who has never heard the word schwannomatosis.

Schwannomatosis is rare enough that most clinicians will encounter it only a handful of times in their career — if they recognize it at all. This resource exists to close that gap: diagnostic criteria, recognition guidance, referral pathways, and presentation materials for teaching, rounds, and continuing education.

Aligned with published standards fromChildren’s Tumor Foundation · Plotkin SR et al. Genet Med.2022 · REiNS International

Are you a patient? This page is written for clinicians — but you are welcome to share it directly with your doctor, your GP, or anyone who needs to understand what schwannomatosis is and why it takes so long to diagnose. You do not need permission to hand them this URL. Read the patient version →

✦

Why This Matters

The Diagnostic Gap Is Measured. It Is Not Acceptable.

The data below comes from a 2022 study of 97 schwannomatosis patients at Massachusetts General Hospital and Johns Hopkins — two of the leading NF specialty centers in the world. These patients had access to major academic medical centers. They still waited an average of 16.7 years.

16.7

years

Median time from first symptom to correct diagnosis

9.8

years

Median time from first seeking medical care to diagnosis

36%

Of patients received at least one documented misdiagnosis before the correct one

providers

Median number of clinicians seen before a correct diagnosis was made

of 97

Patients who received genetic testing during their diagnostic workup

~1:126,000

Estimated population prevalence (likely underestimated) — Plotkin SR et al., Genet Med, 2022

Source: Merker VL, Jordan JT, et al. Am J Med Genet A. 2022;188(8):2414–2425. 97 patients. MGH and Johns Hopkins NF Clinics. PubMed →

2022

NF2SMARCB1LZTR1

Merker VL et al.

“Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis”

American Journal of Medical Genetics Part A 2022;188(8):2414–2425. doi: 10.1002/ajmg.a.62860

Read paper ↗PubMed ↗

Abstract & key data

Merker VL, Bergner AL, Bhatt S, Cooper A, Coy S, Giancola S, Heberton M, Kim MJ, Leary S, Marcario J, Panageas KS, Park C, Peacock ZS, Plotkin SR, Romo T, Stemmer-Rachamimov A, Torres-Reveron A, Warr MR, Yun J, Jordan JT

Abstract — summary (full text paywalled)

A retrospective analysis of 97 patients with confirmed or probable schwannomatosis seen at two U.S. tertiary care NF clinics. The study documented the specific delays, diagnostic errors, and missed opportunities between first symptom onset and confirmed schwannomatosis diagnosis. Barriers identified included intermittent or non-specific initial symptoms, younger age at symptom onset, psychiatric misattribution of pain, pathology errors on individual tumor specimens, and failure to trigger genetics referrals after the first schwannoma. The study recommended interventions in clinician education, genetic testing availability, expert pathology review, and automatic referral triggers. Note: full abstract paywalled. Summary compiled from published preprint (medRxiv) and published paper findings. Free preprint available at medRxiv link above.

16.7Median years — first symptom to diagnosis

7.5 – 26.0 years95% CI

9.8Median years — first medical consultation to diagnosis

3.5 – 16.2 years95% CI (consult to diagnosis)

36%Patients misdiagnosed at least once

18.6%Misdiagnosis: underlying genetic condition

16.5%Misdiagnosis: pain etiology

11.3%Misdiagnosis: tumor imaging or pathology

19.6%Cases with clear missed diagnostic opportunities

97 patients, 2 U.S. tertiary NF clinicsStudy population

What this means clinically: A patient presenting to your practice with schwannomatosis has almost certainly already seen multiple clinicians who did not make the diagnosis. They may carry a psychiatric diagnosis, a fibromyalgia label, or a history of being dismissed. The diagnosis is rarely the first one they received.

✦

Clinical Overview

Schwannomatosis Is Not NF1. It Is Not the Old NF2.

Schwannomatosis (SWN) is a distinct family of conditions characterized by the predisposition to develop multiple schwannomas — tumors of the Schwann cells that sheath peripheral nerves. It is genetically, clinically, and prognostically separate from Neurofibromatosis Type 1 (NF1), which produces neurofibromas, not schwannomas.

In 2022, an international consensus panel led by Dr. Scott Plotkin reclassified the schwannomatosis family under a unified nomenclature. What was formerly called “Neurofibromatosis Type 2” is now NF2-SWN. The other subtypes — SMARCB1, LZTR1, and the genetically unresolved NEC and NOS categories — are now recognized as part of the same disease family, sharing Schwann cell pathology but differing in genetics, severity, and associated tumor types.

The defining clinical feature of schwannomatosis is chronic, severe, often treatment-refractory pain — frequently disproportionate to what imaging suggests. This pain is mechanistically distinct from common neuropathic pain and does not respond reliably to standard analgesic protocols. It is the primary reason patients seek care, and it is the primary reason they are misdiagnosed.

2022 Consensus Subtypes

The 2022 Plotkin consensus formally recognized five clinical subtypes: NF2, SMARCB1, LZTR1, NEC, and NOS. The same paper also updated diagnostic criteria for the rarer subtypes SMARCE1 and DGCR8, which are not yet on most standard genetic panels.

NF2NF2-SWN

CriteriaBilateral vestibular schwannomas (defining), or molecular/Manchester criteria

HallmarkBilateral vestibular schwannomas → hearing loss, balance

Formerly "Neurofibromatosis Type 2." Reclassified 2022.

SMARCB1SWN-SMARCB1

Criteria1 pathology-confirmed non-intradermal schwannoma + pathogenic SMARCB1 germline variant

HallmarkMultiple schwannomas; meningiomas possible; spinal involvement common

Most severe subtype; meningioma risk elevated.

LZTR1SWN-LZTR1

Criteria1 pathology-confirmed non-intradermal schwannoma + pathogenic LZTR1 germline variant

HallmarkMultiple schwannomas; spinal schwannomas; generally milder than SMARCB1

Can appear sporadic or familial; LZTR1 variants found in both germline and mosaic forms.

Status bucketSWN-NEC

CriteriaMeets clinical SWN criteria + comprehensive testing of blood/saliva AND tumor tissue from ≥2 distinct sites — no pathogenic variant found. Tissue from previously banked pathology specimens counts; new surgery is not required.

HallmarkClinically indistinguishable from gene-positive SWN; the gene exists but has not yet been discovered. May include hybrid schwannoma-neurofibroma tumors.

NEC = Not Elsewhere Classified. This is a classification status, not a gene type. Science has not found all SWN genes yet — NEC means testing was thorough and complete, not that the disease is undefined. Blood testing alone does NOT establish SWN-NEC; tissue from ≥2 sites is required because of mosaicism — the variant may not appear in blood if it is only present in some tumors.

Status bucketSWN-NOS

CriteriaMeets clinical SWN criteria + genetic testing is not yet complete — results pending, testing not yet ordered, or comprehensive workup not yet done.

HallmarkWorking diagnosis. Reclassified to NEC once comprehensive testing (blood/saliva + tumor tissue from ≥2 sites) is complete and negative, or to a named subtype if a variant is found.

NOS = Not Otherwise Specified. This is a classification status, not a gene type. NOS is where patients sit while the workup is in progress. The distinction between NOS and NEC is testing completeness, not disease severity or tumor type.

Classification per: Plotkin SR, et al. Genet Med. 2022;24(7):1406–1420. PubMed →

✦

Recognition

When to Suspect Schwannomatosis

Any one of the following should prompt consideration of a schwannomatosis workup and referral to an NF specialty clinic:

Two or more pathology-confirmed schwannomas at any age
Single schwannoma under age 30 — especially spinal or cranial
Schwannoma in a patient with a first-degree relative with NF2 or schwannomatosis
Severe, treatment-refractory pain out of proportion to imaging findings
Hybrid tumors on pathology (schwannoma-neurofibroma features)
Spinal mass with neuropathic pain in a young patient without trauma history
Patient previously diagnosed with NF1 who has only schwannomas, not neurofibromas
Bilateral vestibular schwannomas at any age (NF2-SWN until proven otherwise)

Genetic testing: The UAB Medical Genomics Laboratory runs the highest-volume NF genetic testing program in the world. Their schwannomatosis NGS panel (SCH-NG) covers NF2, SMARCB1, and LZTR1 from blood, saliva, or tumor tissue. Blood alone is insufficient to establish SWN-NEC — tumor tissue from at least two anatomically distinct sites must also be tested. UAB SCH-NG panel →

✦

At a Glance

How the Subtypes Differ

NF2-SWN sits in a different clinical world than SMARCB1-, LZTR1-, SMARCE1-, and DGCR8-related schwannomatosis. They share a tumor type. Almost everything else diverges. NOS and NEC are included as classification states — NOS means genetic testing was not done; NEC means comprehensive testing was negative.

Feature	NF2-SWN	SMARCB1-SWN	LZTR1-SWN	NOS / NEC	SMARCE1 / DGCR8
Basics
Gene / Chromosome	NF2 / Chr 22q12	SMARCB1 / Chr 22q11	LZTR1 / Chr 22q11	Unknown	SMARCE1 (Chr 17) / DGCR8 (Chr 22q11)
Inheritance	AD	AD	AD or ARUnique among SWN genes	—	AD
Standard panel coverage	Yes	Yes	Yes	N/A	Not on standard panels
Dx requires genetic testing	No — clinical criteria sufficient	Yes	Yes	NOS: not doneNEC: done & negative	Yes
Tumors
Bilateral vestibular schwannomas	Defining feature	Excluded	Typically excluded	Excluded	Not established
Spinal & peripheral schwannomas	Present	Hallmark	Hallmark	Hallmark	Present
Meningiomas	Very common45–58% of cases	PresentSpinal > intracranial	None documented	Possible	Spinal & cranialSMARCE1-specific
Ependymomas	Common33–53% of cases	Rare	Rare	Rare	Not established
Symptoms
Dominant symptom	Hearing loss, tinnitus, balance problems	Chronic pain	Chronic pain	Chronic pain	Chronic pain
Pain as primary feature	No	Yes	Yes	Yes	Yes
Hearing loss	Yes — hallmark	Only if VS present	Only if VS present	Only if VS present	Not established
Eye findings	Cataracts, retinal hamartoma, epiretinal membrane	None	None	None documented	None documented
Typical onset	Teens–20s	20s–40s	20s–40s	Variable	Not established
Clinical Care
Malignancy risk	Low	Low–moderateRhabdoid tumor risk in families; SMARCB1 is a tumor suppressor	Low	Unknown	Not established
Radiation avoidance	Standard caution	CriticalIncreases malignant transformation risk	Standard caution	Unknown	Not established
Annual audiology needed	Yes	Only if VS risk	Only if VS risk	Only if VS risk	Not established

Sources: Plotkin SR et al., Genetics in Medicine, 2022; GeneReviews: NF2-Related Schwannomatosis (updated 2025); GeneReviews: LZTR1- and SMARCB1-Related Schwannomatosis (updated Dec 2025); Evans DG et al., ERN GENTURIS Clinical Practice Guidelines, 2022.

Differential Diagnosis

Clinical Presentation — NF2-SWN vs. SWN

Schwannomatosis presents very differently depending on subtype. Non-NF2 SWN (SMARCB1, LZTR1, NEC, NOS) is defined by severe chronic pain and peripheral or spinal schwannomas. NF2-SWN is defined by bilateral vestibular schwannomas and their consequences — hearing loss, balance problems, meningiomas, and ependymomas. Both involve schwannomas. The clinical picture is distinct enough that the two should never be grouped under a single treatment or surveillance protocol.

Symptom / Sign	NF2-SWN	SWN — SMARCB1 / LZTR1 / NEC / NOS	Suggestive Tumor(s)
Hearing Loss (Bilateral)	Very Common	Rare / Uncommon	Vestibular Schwannomas
Tinnitus	Very Common	Rare	Vestibular Schwannomas
Balance Problems / Vertigo	Very Common	Rare	Vestibular Schwannomas
Facial Numbness or Paralysis	Common (cranial nerves)	Rare	Cranial Schwannomas (Trigeminal / Facial)
Vision Issues / Cataracts	Common	Rare / Uncommon	Associated Cataracts
Headaches	Common — meningiomas, cranial nerve compression	Common — central sensitization from chronic pain	Meningiomas (NF2-SWN); central sensitization (SWN)
Chronic Severe Pain	Common — cranial and spinal nerve compression	Hallmark — often severe, widespread, and multifocal	Peripheral Schwannomas, Spinal Schwannomas, Hybrid Tumors
Allodynia / Touch and Temperature Hypersensitivity	Occasional	Common — hallmark of central sensitization in SWN	Peripheral nerve sensitization; not tumor-site specific
Muscle Pain (Myalgia)	Occasional	Common — from involuntary nerve firing, periosteal pressure, and myofascial guarding	Peripheral nerve hyperexcitability; tumor proximity to bone or muscle
Peripheral Nerve Hyperexcitability (fasciculations, involuntary movements)	Rare	Documented — likely underreported; paroxysmal movements with preserved awareness	Nerve irritation from tumor proximity or chronic peripheral nerve disease
Post-Exertional Symptom Amplification	Uncommon	Common — delayed crash after minimal activity, partial recovery	Not tumor-site specific — chronic nervous system depletion
Sleep Disruption from Pain	Occasional	Common — pain at rest, spontaneous nerve firing, allodynia from contact	Not tumor-site specific — central sensitization
Numbness / Tingling / Paresthesia	Common	Very Common	Peripheral & Spinal Schwannomas
Weakness (Arms / Legs)	Common	Very Common	Spinal or Peripheral Schwannomas
Severe Spinal Pain	Common	Very Common	Spinal Schwannomas
Pain Before Tumor Visible on Imaging	Less Common	Common — pain can precede detectable tumor by months to years	Small tumors or tumors on unimaged nerve branches; peripheral sensitization
Multiple Tumors (no skin involvement)	Common	Common	Peripheral, Spinal Schwannomas, Hybrid Tumors
Hybrid Neurofibroma-Schwannoma	Rare (possible)	Strongly Suggestive of SWN-NEC	Hybrid Tumors
Cutaneous Neurofibromas (skin tumors)	Not Present	Not Present	N/A — Associated with NF1, not SWN

Based on 2022 international consensus classification (Plotkin SR et al., Genet Med. 2022) and clinical reference prepared for the Order of the SWNs Foundation. For differential diagnosis guidance only — individual patients vary significantly.

✦

Referral

Where to Send Your Patient

Schwannomatosis requires subspecialty knowledge that extends beyond general NF care. The Order’s clinic directory is not limited to any single NF clinic network — it covers any clinic or individual physician who claims schwannomatosis expertise, regardless of institutional affiliation.

Our clinic directory distinguishes between providers with documented published schwannomatosis research or explicit SWN scope, and providers where SWN expertise has not been independently confirmed. Each listing notes the basis for inclusion, the age groups seen, and what to ask before referring.

Open the SWN Clinic Directory →

Includes US and international centers, provider profiles, and a guide on what to ask the clinic before you send your patient.

✦

Presentation & Teaching Materials

Resources for Teaching and Continuing Education

The following materials are in development. When finalized, they will be reviewed against published clinical standards before publication. If you would like to contribute clinical expertise to the review process, contact the Foundation directly.

Available Now

Schwannomatosis Media Package

A schwannomatosis media package is available for NF clinics, medical practices, medical schools, and newsrooms — key statistics, condition overview, subtype classification reference, diagnostic red flags, and expert referral contacts. Request a copy and we will send it directly.

Request the Media Package →

In Development

CME Slide Deck — Schwannomatosis Overview

A complete presentation for grand rounds, residency teaching, or continuing medical education. Covers classification, diagnosis, pain mechanisms, referral, and current clinical trials.

In Development

One-Page Clinical Reference

A single-page quick reference for clinic use — diagnostic criteria, red flags, when to refer, and genetic testing pathway. Formatted for printing and posting.

In Development

Referral Protocol

A structured referral pathway from primary care or general neurology to NF specialty care — what to document, what testing to initiate before referral, and how to communicate urgency.

In Development

Patient Handout — What to Expect at an NF Clinic

For clinicians to give to newly diagnosed or referred patients. Sets expectations for the specialist visit, lists what to bring, and explains genetic testing.

Want to be notified when materials are ready? Or contribute clinical expertise to the review process? Contact the Foundation →

✦

Expert Resources

Published Guidelines & Clinical References

2022 International Consensus Classification — Plotkin SR et al.Genetics in Medicine. 2022. The definitive reclassification and updated diagnostic criteria for the schwannomatosis family. Primary reference for all subtype terminology and nomenclature.↗2022 ERN GENTURIS Clinical Practice Guidelines — Evans DG et al.European Journal of Human Genetics. 2022. The European clinical standard for SWN diagnosis, surveillance, and management across all subtypes. Available in 18 languages with a pocket guide and plain-language patient summary.↗Diagnostic Delay Study — Merker VL et al.Am J Med Genet A. 2022. 97 patients, MGH and Johns Hopkins. Quantifies the 16.7-year median diagnostic delay.↗QUEST — NF2-SWN Quality of Life Measure — Merker VL et al.medRxiv preprint. 2026. 21-item disease-specific PRO measure validated in 174 NF2-SWN patients; being adopted in upcoming clinical trial protocols. Preprint — not yet peer-reviewed.↗REiNS International CollaborationResponse Evaluation in Neurofibromatosis and Schwannomatosis. Establishes outcome measures for clinical trials. Clinician membership available.↗Active Clinical Trials — ClinicalTrials.govCurrent recruiting trials for schwannomatosis including STARFISH (pain, NCT05684692) and INTUITT-NF2 (tumor, NCT04374305).↗Children’s Tumor FoundationPrimary funder of NF and SWN research. Hosts the annual NF Conference and manages the NFCN clinical network.↗

✦

Help Us Improve This Resource

This page is a living document. If you are a clinician, educator, or researcher who works with NF or schwannomatosis patients and you see something wrong, incomplete, or missing — we want to hear from you.

Contact the Foundation →Knowledge Bank →Find a Clinic →

← Foundation Home | Symptoms & Diagnosis → | Find a Clinic → | Knowledge Bank →